RxDoctor Payments Data
★ My doctorsLook up a doctor →

Daphenie Fauvel

Family · Bronx, NYNPI 1295220143

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (44.5%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Abbott accounts for 94.6% of it on its own, with 12 other manufacturers making up the rest. 2025 is the largest year on record at $12,960, more than ten times the $39 reported in 2021. Among family clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$20,753in general payments, 2019–2025

Across 153 payments — averaging $135.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$20K
  • Merck$212
  • Novartis$199
  • Paragonix Technologies, Inc.$160
  • Takeda Pharmaceuticals U.S.A., Inc.$111
  • AstraZeneca$80
  • plus $363 from 7 others

What the payments were for

  • Consulting fees$9,24145%
  • Travel & lodging$4,68623%
  • Food & beverage$4,19620%
  • Education$2,63013%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Abbott102$19,628
Merck12$212
Novartis10$199
Paragonix Technologies, Inc.3$160
Takeda Pharmaceuticals U.S.A., Inc.6$111
AstraZeneca4$80
Alnylam Pharmaceuticals Inc.3$77
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)3$61
Daiichi Sankyo Inc.2$59
Scpharmaceuticals Inc.3$55
Actelion Pharmaceuticals US, Inc.2$54
Pfizer2$37
Irhythm Technologies, Inc.1$21

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,753 in reported general payments places this provider in the 95th percentile of 8,883 family providers in New York.

See all family providers in New York →

Most prescribed under Part D

DrugClaimsCost to plans & patients
Sandostatin Lar DepotOctreotide Acetate,mi-Spheres24$99,714
JardianceEmpagliflozin15$18,725
Sildenafil Citrate20$3,100
Torsemide34$513
Warfarin Sodium61$399
Digoxin25$352
Metoprolol Succinate18$344
Hydralazine Hcl15$221
Pantoprazole Sodium22$202
Potassium Chloride11$190
Carvedilol34$145
Spironolactone21$90
Fluticasone Propionate14$84
Amiodarone Hcl14$79
Losartan Potassium12$72

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisSandostatin Lar Depot$199$99,71424 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,883 family providers in New York.

Other family in Bronx

See the full list for New York →

Where these figures come from

Is this you, or does something look wrong? →